6.98
-0.07
(-0.99%)
Pre-market: 7.32
+0.34
(4.87%)
May 22, 8:00AM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 6.90 - 7.12 |
| 52 week | 6.34 - 15.96 |
| Open | 7.07 |
| Vol / Avg. | 8,780.00/3.89M |
| Mkt cap | 1.05B |
| P/E | - |
| Div/yield | - |
| EPS | -1.28 |
| Shares | 150.37M |
| Beta | 1.47 |
| Inst. own | 57% |
Events
Aug 7, 2013
Q2 2013 Amarin Corporation PLC Earnings Release
Jul 9, 2013
Amarin Corporation PLC Annual Shareholder Meeting
- 8:00AM EDT -
May 9, 2013
Q1 2013 Amarin Corporation PLC Earnings Conference Call
May 9, 2013
Q1 2013 Amarin Corporation PLC Earnings Release
Feb 28, 2013
Q4 2012 Amarin Corporation PLC Earnings Conference Call
Feb 27, 2013
Amarin Corporation PLC at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -14.98% | -81.96% |
| Return on average equity | - | - |
| Employees | 111 | - |
| Carbon Disclosure Rating | - | - |
Address
2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
DUBLIN, CT 06355
Ireland
+353-1-6699020 (Phone)
+1-860-5724940 (Fax)
DUBLIN, CT 06355
Ireland
+353-1-6699020 (Phone)
+1-860-5724940 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company�s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).
Officers and directors
| Joseph S. Zakrzewski | Chairman of the Board, Chief Executive Officer | |
| John F. Thero CPA | President, Principal Financial Officer, Assistant Secretary | |
| Steven B Ketchum Ph.D. | President - Research and Development, Senior Vice President | |
| Joseph T. Kennedy | Senior Vice President, Chief Compliance Officer, General Counsel, Secretary | |
| Paul E. Huff | Senior Vice President, Chief Commercial Officer | |
| Stuart D. Sedlack | Senior Vice President - Corporate Development | |
| Lars G. Ekman M.D., Ph.D. | Lead Independent Non-Executive Director | |
| David M. Stack | Independent Director | |
| Joseph Anderson Ph.D. | Non-Executive Independent Director | |
| Carl L. Gordon Ph.D. | Non-Executive Independent Director |